Prospects for the development and use of gram-negative bacterial virulence protein secretion inhibitors for prophylaxis and treatment of infectious diseases.
As the breadth and number of bacterial pathogens exhibiting antibiotic resistance is rapidly increasing, our ability to treat new and re-emerging infectious diseases is being threatened. Therefore, the development of new therapeutic strategies, including drugs acting on new targets, is required. In this review, the feasibility of gram-negative bacterial secretion systems for the development of anti-virulence agents and possible arenas for their utility in therapeutic intervention of gram-negative bacterial infections such as gastroenteritis, nosocomial infections, and venereal diseases are discussed.
Felise
Heather B
HB
Department of Microbiology, University of Washington, Seattle, Washington 98195, USA. hrb@u.washington.edu.
Miller
Samuel I
SI
D019072:Antibiotic Prophylaxis; D001426:Bacterial Proteins / Q000378:metabolism*; D003140:Communicable Disease Control; D003141:Communicable Diseases / Q000628:therapy*; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000472:pathogenicity*; D006801:Humans; D037521:Virulence Factors / Q000037:antagonists & inhibitors / Q000378:metabolism
D001426:Bacterial Proteins; D037521:Virulence Factors